Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. Please be advised today's conference is being recorded. I would now like to hand the conference over to our speaker today, David Connolly with Rhythm Pharmaceuticals. Please go ahead.

Thank you, and good morning. I'm David Connolly, Head of IR and Corporate Communications here at Rhythm Pharmaceuticals. For those of you participating via conference call, the accompanying slides can be accessed and controlled by going to the Events section of the Investors page on our website at ir.rhythmtx.com. This morning we issued a press release that provides our third quarter 2021 financial results and business update, which is available on our website. As listed on slide 2 with me today here in Boston for the conference call are David Meeker, Chair, President and Chief Executive Officer of Rhythm; Linda Shapiro, our Chief Medical Officer; Jennifer Chien, Executive Vice President Head of North America; and Hunter Smith, our Chief Financial Officer. With slide 3, I'll remind you that this call contains remarks concerning future expectations, plans and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors including those discussed in our most recent annual report on file with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. With that, I'll turn the call over to David who will begin on slide 5.

Thank you, Dave, and good morning everyone. We're very pleased to report another strong quarter of execution for Rhythm, and I'm happy with the progress we’ve made so far. The first slide highlights four key areas of focus for us. The first is our commercial experience with IMCIVREE. Second, we are looking forward to the anticipated launches of Bardet-Biedl and Alstrom's in 2022. Third, we aim to expand our global presence, primarily in Europe but also beyond. Fourth, we are committed to advancing a robust clinical development program that can significantly increase the patient population we can address. Quarter three showcased multiple highlights, and we continued to execute effectively. The US IMCIVREE launch is on track and meeting expectations. We expected to have tens of patients on treatment, and that outlook remains consistent. We were pleased to see net sales surpass $1 million for the quarter, but more importantly, we are excited about the insights we are gaining from this initial commercial experience, which will serve as a foundation for our upcoming Bardet-Biedl launch. In our international markets, particularly Europe, we have filed reimbursement dossiers in key markets as well as some smaller ones and are in advanced negotiations in Germany, France, and the UK. As we prepare for the BBS launch in mid-2022, we have submitted regulatory applications in both the US and Europe. In the US, we have built a highly experienced field team, and Jennifer will share more details on that. With a year before the anticipated launch, we feel well-positioned, and I'm looking forward to that milestone. We also had a strong presence at medical meetings, with 22 presentations at three major conferences. Positive data was shared from various clinical datasets, with prominent experts presenting setmelanotide data. We showcased our first data on health-related quality of life as well as additional data on hunger and weight scores across different genetic conditions. Linda will provide more context on that during her presentation. Finally, our clinical development programs are on track, with EMANATE DAYBREAK pediatrics and weekly trials progressing toward first patient in, and I will share more information regarding our testing program later. Before we transition to the next slide, I want to highlight the effectiveness of building within the rare disease community. In this space, there are typically a limited number of centers of excellence and key opinion leaders who can serve multiple roles. This allows us to focus our efforts effectively around these sites. These centers not only conduct the trials but also serve as the primary physicians and healthcare providers for diagnosing and treating these patients. We are pursuing a hub-and-spoke model, where the clinical trial site serves as the center, and we collaborate with a network of surrounding healthcare providers and potential referral sites. Over time, some of these may develop into their own centers of excellence based on interest and activity. Moving to the next slide, here's a brief update on our testing program. We have several iterations of our genetic screening panel. In May, we expanded from a 40-gene panel to an 80-gene panel, which includes all genes relevant to Rhythm and those that may interest obesity treaters as potential drivers of obesity in specific patients. The data shows that approximately 55% of patients with a history of early onset obesity and hunger are likely to test positive for one of the genes of interest, qualifying them for the EMANATE or DAYBREAK trials. Additionally, 1.96% of this group are biallelic for either the Bardet-Biedl or ALMS1 gene, which is linked to Alstrom's syndrome. This is a notable percentage, and while we still have much to learn about these patients, this opens up new avenues for understanding the disease, and Rhythm intends to lead this exploration. Moving on to the next slide, I want to remind you that we have a broad and legitimate pipeline, which Linda will elaborate on in her section. With that, I will turn it over to Linda.

Thank you, David. This is an exciting time for Rhythm, as our efforts around Bardet-Biedl syndrome are coming together on many fronts, putting us in a position to bring to patients the first ever therapy to address the unmet needs of hyperphagia and severe obesity that affect the lives of patients and families living with this disease. Bardet-Biedl Syndrome or BBS, is a clinical syndrome with many features, including severe obesity from an early age, and an insatiable hunger or hyperphagia, which impact the health and quality of life for patients, their families and caregivers. There is currently no effective treatment and we know from interviews and our work on health-related quality of life in patients and families, with BBS, that was presented this week for the first time, just how dire the need is to control hunger and to stop thinking about food all the time. This quarter, as David said, we are one step closer to delivering a transformative new treatment option to patients having completed our regulatory submissions in the US and EU. Setmelanotide has demonstrated clinical efficacy and safety, as well as meaningful improvements for patients and their families, caregivers, and health care providers. And we look forward to reviewing some of these data today. Slide 13. The severe impact that BBS has on the lives of patients and families is significant and we've made tremendous strides this quarter in documenting, qualifying and quantifying this impact. But the patients, caregivers, and families clearly speak best for themselves. As their quotes on this slide, from in-depth qualitative interviews that we conducted with patients with BBS and/or their caregivers point to the stress and guilt of denying food to children with hyperphagia and point to how the world revolves around food which limits their focus on anything else. Pause here for an opportunity for you to read through some of these quotes. During our company all-hands meeting, we heard last month from the mother of a child with Bardet-Biedl syndrome and her story reinforced our understanding of the impact BBS has on families and underscored the unmet need that exists in this community. She told us about the significant weight gain evident by two years old that continued as an off-the-chart rate of weight growth and the challenges she faced in school with weight gain including physical, as well as social difficulties. She told us it was very tough. These first-hand accounts reinforced our understanding of the impact BBS has on families and underscore the unmet need that exists in these cases. Slide 14. This quarter we completed regulatory submissions for Bardet-Biedl syndrome and Alstrom syndrome in both the United States, as well as the European Union. In September, we submitted a supplemental new drug application to the FDA for IMCIVREE, the branded name of setmelanotide for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with BBS or Alstrom syndrome. We requested priority review from the FDA as part of the application. Based on FDA timelines, we will know in November if our supplemental NDA has been accepted with priority review. And if granted, that would mean a target FDA review period of six months from that date of acceptance. In October, we submitted a Type II variation application to the European Medicines Agency for IMCIVREE for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with BBS or Alstrom syndrome. The review timeline in Europe is calendar based and we would expect a decision from the European Commission in the second half of 2022. We are confident in these submissions as they are based on data from the pivotal Phase III trial in which setmelanotide achieved clinically meaningful and statistically significant reductions in body weight and in the unrelenting hunger associated with these syndromes. And these submissions include a series of comprehensive narratives for each individual patient supporting our belief that IMCIVREE has the potential to offer the first therapeutic option for the early onset, severe obesity and unrelenting hunger that characterize these syndromes. On Slide 15, here's a reminder of the trial design of our Phase III trial evaluating setmelanotide therapy in patients with Bardet-Biedl syndrome and Alstrom syndrome. This trial began with a 1:1 randomization in a double-blind placebo-controlled period of 14 weeks as highlighted in the light blue area and then progressed through a minimum of 52 weeks on setmelanotide therapy. All patients were titrated on setmelanotide at the beginning of the open-label portion and proceeded to complete at least 52 weeks on therapy for those who began on placebo and a total of 66 weeks on therapy for those who began on setmelanotide. Patients were evaluated for the primary and key secondary endpoints at 52 weeks on therapy, as shown here in the red boxes. Slide 16. The data from the 14-week double-blind placebo-controlled period are shown. Significant BMI reductions in patients with BBS on setmelanotide therapy versus placebo. Patients in the placebo group had negligible weight loss or BMI reduction at 14 weeks, compared to patients in the treatment group who reduced their BMI by an average of 4.3%. This translates to a statistically significant placebo-corrected setmelanotide treatment effect of 3.8% BMI reduction in 14 weeks. On Slide 17, as we said previously, this trial achieved all primary and key secondary endpoints with statistically significant and clinically meaningful reductions in body weight and hunger at 52 weeks. These data on patients with BBS from the Phase III trial are presented this week at the ObesityWeek Conference in the symposium by Dr. Robert Haws from the Marshfield Clinic the leading Bardet-Biedl syndrome key opinion leader in the United States. As you can see, we saw clinically significant reductions in body mass index across all 31 patients with BBS in this trial with a mean reduction of greater than 9% in both adults as well as children adolescents at 52 weeks of therapy on setmelanotide. Slide 18, setmelanotide achieved clinically meaningful reductions in hyperphagia, that insatiable hunger that dramatically affects the lives of patients with Bardet-Biedl syndrome and their families. As we saw these data in both the initial 14-week double-blind period set here in the light blue blocks and out to 52 weeks. At 14 weeks, these data showed that patients in the placebo group had a modest reduction in hunger scores compared to the nearly 35% reduction achieved by the treatment group. Interestingly, when we compare the data trends over 52 weeks, there is a clear separation of hunger during the double-blind placebo-controlled period highlighted in the light blue box, followed by the placebo group reaching treatment levels rapidly after crossover to the open-label setmelanotide treatment period with the white background. Also, after the placebo-controlled double-blind period at week 14, you can see a brief rebound of hunger when patients on setmelanotide were retitrated onto the drug. This speaks to the sensitivity of hunger in Bardet-Biedl syndrome patients as well as the sensitivity of the setmelanotide response. Slide 19. At the ObesityWeek Conference this week, we are also presenting the first ever health-related quality of life results to measure the impact of setmelanotide therapy for patients with BBS. This is particularly important in this ultra-rare disease, as our research underscores the need to address the health-related quality of life burden experienced by patients. The data show after one year of treatment with setmelanotide, 85% of patients reported clinically meaningful improvements in or preserved their non-impaired health-related quality of life status. For adult patients, changes to their impact of quality of life or Impact of Weight on Quality of Life score from baseline to 52 weeks was clinically meaningful with a mean increase of 12 points. For pediatric patients, we saw a clinically meaningful increase of the Peds Quality of Life score from baseline to 52 weeks of 11.2 points. Clinically meaningful improvements in clinical outcomes such as body mass index and hunger also mirrored improvements in health-related quality of life. Importantly, at the patient level, improvements were sustained over the 52-week prior period. With slide 21, I'd like to shift gears from BBS to our robust clinical development programs to treat more patients with obesity and hyperphagia due to genetically impaired melanocortin-4 receptor pathways. I want to begin by touching on a recent publication that illustrates the severity of disease for patients with heterozygous variants in several of our patients. Setmelanotide's growing body of evidence in these indications and then I'll summarize with a short update on our next wave of clinical trials. On slide 22, there is an article titled 'Implications of Heterozygous Variants in the Genes of the Leptin Melanocortin Pathway in Severe Obesity' by Dr. Sophie Courbage and the team in the lab of Dr. Karine Clément of Sorbonne University in Paris it was published online this summer in the Journal of Clinical Endocrinology and Metabolism. This article details for the first time the phenotype of patients with early onset severe obesity and hyperphagia to the heterozygous variant in the melanocortin-4 receptor pathways, including leptin receptor POMC and PCSK1 genes comparatively to patients with homozygous or biallelic variant. Importantly, the comparison shows similarly severe obesity with similar early onset and severe hyperphagia, all of which underscore the genetics and the effect of the impaired pathway, a burden of the rare genetic disease or obesity and the need for growth. This research underscored the effects of a genetically impaired MC4R Pathway and the burden of rare genetic diseases of obesity and the need for therapy. On Slide 23, in addition to Drs. Courbage and Clement, we are grateful for the support of the world's leading key opinion leaders in genetic obesities. Between The European Society for Paediatric Endocrinology, The Obesity Medical Association and The Obesity Society Congress this week, 22 presentations of setmelanotide and uncovering rare obesity data have been presented by physicians, including Dr. Martin Wabitsch of the University of Ulm, Dr. Peter Kühnen of Humboldt University in Berlin, Dr. Jesús Argente of the Autonoma University in Madrid, Dr. Sadaf Farooqi from the University of Cambridge, Dr. Elizabeth Forsythe from the University College of London, and Dr. Robert Haws from Marshfield Clinics, who I mentioned previously. We've covered nearly everything today, except these efficacy results from complete top-line analysis of our Phase II basket study, which were presented at ESPE in September. These data show weight loss and hunger reduction at three months on therapy in patients with SRC1 or SH2B1 gene deficiencies, as well as a clear separation between patients who responded to setmelanotide treatment at three months and those who did not. All these presentations are available on our website. Lastly on Slide 24, our clinical development programs are on track, most notably the DAYBREAK and EMANATE studies, which aim to address severe obesity and hyperphagia across 36 genes with strong or very strong relevance to the melanocortin-4 receptor pathways. Site initiations are underway with investigator meetings planned for this month and next month and first patients in anticipated in the fourth quarter. There's a tremendous amount of activity ongoing and a lot of excitement. And with that, I'll turn the call over to Jennifer. Thank you.

Thank you, Linda. I start on Slide 26. Our strategy of making IMCIVREE commercially available in the US is meeting our expectations through these first two full quarters. As David said, in the third quarter we reached $1 million in net sales and we are pleased to report that patients are getting access to IMCIVREE with positive coverage decisions and reimbursement. We remain focused on HCP engagement and walking them through the process from start forms and authorizations and if needed support throughout the appeals process. Our corporate accounts and patient service teams which are new this past quarter are making a significant difference. And most importantly, in communications with patients on IMCIVREE, we are hearing positive feedback. An adult man, who was constantly distracted by hunger for as long as he can remember, now forgets to eat. And this next report really speaks to what we are providing. Among those who told us IMCIVREE therapy resulted in weight loss and reduced her daughter's obsession and constant drive to eat. She was able to tell her 11-year-old daughter, 'See, this is not your fault.' On Slide 27, looking to BBS, Linda shared some details on how devastating BBS is for patients and families who have no approved therapy. As we have previously communicated, prevalence estimates for BBS are 2,500 in the US and the same in Europe. The community has come together around the need for a therapy and relative to patients with biallelic POMC, PCSK1 or LEPR deficiencies, they are known to the healthcare system. We know there are more than 600 patients in the US-based CRIBBS registry. And in the EU4 and the UK, we estimate there are a total of 1,500 diagnosed BBS patients. As we know from experience in rare disease, these initial prevalence estimates are usually low and we consider them a starting point as we actively engage with the community to diagnose and find more. On Slide 28. Our US commercial availability strategy for POMC, PCSK1 and LEPR deficiency obesity enabled us to put the infrastructure in place that allows for access to IMCIVREE now. It also lays the groundwork to set up for success for the BBS launch. Looking ahead, our near-term priorities are clear: establish access via patient support and payer engagement, elevate the need to treat the hyperphagia and severe obesity that comes with BBS, and accelerate and facilitate diagnosis. Next slide. Through our Patient Support Team, we are making direct contact with consented patients or their caregivers, as HCPs prescribe IMCIVREE for them. Our team provides comprehensive case management, offering education and coordination of treatment access activities to help identify and resolve barriers to therapy. We also provide support to prescribers, as they navigate the prior authorization process to facilitate timely payer coverage. Our continued support and engagement are key milestones in the patient journey are designed to ensure adherence. Next slide. In addition to having high-tech patient services established now, we have fully hired trained and deployed in the field our team of BBS territory managers. They are a highly engaged and experienced team with more than 20 years of pharma sales experience on average on top of rare disease and launch experience. And with experience in ophthalmology, nephrology and endocrinology, we are seeing results. These territory managers are engaging physicians and focused on identifying BBS patients and expanding the care network for BBS patients. Their focus on physician engagement starts with ongoing engagement of top-tier targets of approximately 125 HCPs with BBS patients in their care. In addition, we have tiered targets we believe are likely to have BBS patients that have been identified through machine learning, as well as follow-up of HCPs with biallelic BBS genes identified through our Euro program. Next slide. Armed with the full data from the Phase III BBS trial, we recently completed double-blinded qualitative primary market research with 30 US HCPs who treat patients with Bardet-Biedl syndrome. It is clear that obesity is universally viewed as a serious health concern for individuals with BBS with no treatment options. When presented with the product profile of IMCIVREE, 75% of them said they would prescribe setmelanotide as a first-line therapy for BBS patients to treat obesity. This is due to the mechanism of action, our expected age range of six plus and weight loss efficacy. Moving to slide 32. And lastly, I just want to touch on the work of our Area Development Managers, who are charged with executing a targeted strategy to drive genetic testing of individuals with early onset severe obesity. This of course will help drive enrollment for EMANATE and DAYBREAK. But also, we know this will help us find patients with biallelic POMC, PCSK1 or LEPR. And as David mentioned earlier, we are also finding HCPs with patients who have genetic variance associated with BBS, who may or may not have the clinical diagnosis of BBS. In these cases, the ADMs will hand these HCPs to the BBS territory managers for follow-up, hence a very nice collaboration is seen amongst the field team. I'd now like to turn the call over to Hunter to review our third quarter financial results.

Thank you, Jennifer. I'm on slide 34. During the third quarter, Rhythm reported product revenue net of $1 million. All revenue came from the United States. There were no revenues during the comparable quarter of 2020. Loss from operations was $44 million, an increase of $10 million over the comparable quarter in 2020, due to increases in both clinical trial activity as well as higher headcount in our research and development, commercial and general and administrative functions. Operating loss was offset by approximately $9 million tax benefit, reducing the tax provision we made in the first quarter due to our sale of the priority review voucher. Our share count was 50.2 million basic and diluted shares and loss per common share was $0.70, a decrease of $0.07 versus the third quarter of 2020. We concluded this quarter with cash, cash equivalents and short-term investments of $328 million, which we believe to be sufficient to fund Rhythm's operations into the second half of 2023. And now, I'll turn the mic back over to David, so he can conclude. Thank you.

Thank you, Hunter. And hopefully as you've heard, we had a really good quarter in quarter three. Linda highlighted the significant progress we've made across our clinical development program and look forward to that continuing for the balance of Q4 and into 2022. The large presence that we've had in medical meetings and it's obviously important to share new data and you've heard some of that also a critical component in increasing awareness and drawing further attention to the problem of rare genetic diseases of obesity. And as you heard from Jennifer, we are continuing to make good progress in preparing for a very meaningful opportunity we believe that the Bardet-Biedl launch and I have to say in my years of experience working in the area of rare diseases, I think the team that has been built and is in the process of being built has experience with anything that I have worked with and so we have a good challenge in front of us, but we certainly have the team and capabilities who have the ability to execute on that. So, the last slide is just again try to put in perspective Rhythm and the opportunity in front of us. As we've talked about the initial approval for POMC, PCSK1, and LEPR biallelic deficiencies, we believe they're on the order of 600 to 2,500 that the data around that we're still learning and beginning to explore it. But over time that number will grow. It starts small and again we're meeting expectations. Nothing's changed in our forecast or guidance there if you will. But the opportunities ahead of us some are much more significant. Bardet-Biedl and Alstrom's because as a syndrome they are more easily identified and therefore, we start with a much larger number of patients who have been diagnosed based on their clinical presentation. We project on the order of 2,000 to 3,000. But this is a group where again based on past experience, epidemiology can often underestimate the number of patients that may be out there. The work that we're doing with the URO testing, the genetic screening where patients are presenting with that history of early onset obesity and hunger a not insignificant number of them have genetic defects, biallelic defects for Bardet-Biedl and Alstrom. And as I said whether they will ultimately go on to full-blown presentation remains to be seen, but it does provide a bit of a window into perhaps the fact that yes, for sure, there have to be more patients out there who have yet to come to diagnosis. So, we'll continue to push on that. And finally, just to remind you EMANATE trial is five sub-studies and each one of them will read out independently. They're independently powered. And any one of them offers a very meaningful increase over our current opportunity you can see the numbers projected here. So, they're all 20,000 individuals US-only opportunities. And then DAYBREAK trial, which is a very efficient as we've explained in the past way of looking at the additional 31 genes we believe are linked to the pathway and we should in a relatively rapid way I hope and even get insights into a number of these genes as to whether they in fact are driving that underlying early severe obesity presentation. So, with that, I'll turn it back to the operator and open it up for Q&A. Thank you.

Thank you. Our first question comes from the line of Phil Nadeau with Cowen and Co. Your line is open.

Good morning and thanks for taking our questions and congrats on all the progress. Just a few from us. First on the BBS sales force already being deployed. Are there goals for the sales force in terms of number of HCPs contacted or a number of BBS patients engaged by the time of the approval midyear next year?

Jennifer?

For the current BBS territory managers are provided with different targets. The first number of targets starts with the approximately 125 HCPs that were already within our sphere that have BBS patients. So, the engagement of those initial positions will remain a key target for them. In addition to that as we outlined on the call, there's an opportunity in terms of disease educating a broader set of physicians who may have BBS patients. This includes follow-up of physicians who have biallelic patients through discovered through our URO program. There are, in addition, we have been working through machine learning, to also learn about the histories and journeys of patients who have BBS. And through these learnings, we are able to do more accurately identify HCPs, who may have BBS patients within their care that can also be a target for follow-up.

Perfect. That's very helpful. And then second on the quality of life data, what drove the improvements in quality of life for BBS patients? Was it hyperphagia specifically, BMI changes or some combination of the two?

Yeah. Thanks. Linda?

Sure. That's a great question. The way the questionnaires are designed, it does not drive down into that detail, but to your point it likely is a combination of both – and the weight specifically the adult questionnaire, the Impact of Weight on Quality of Life is designed about weight, but there is a component where the hyperphagia is – where the hyperphagia could have improved the quality of life as well. Perfect. And then – sorry, go ahead.

No, I was just going to say about half of the hunger question here could only be done by those patients who do not have cognitive impairment and in the BBS world there are some number of those, and so in that smaller subset, where we could link the hunger to the quality of life benefit it did mirror.

Perfect. Okay. And then last question for us. In terms of the EMANATE and DAYBREAK trials, what's limiting to getting those first patients in the door? Is it finding the patients or are there other start-up activities particularly at the sites that are gating?

Yes. Great question. So we're going through the standard process of start-ups. So we're completely aligned to our timelines and on track, so there is no limitation per sequential, we're just following through the steps. We have actually a number of patients lined up at the sites. So once we turn on the green light, they'll be ready to go and we anticipate quite a bolus in the beginning for those patients, who are already lined up.

Perfect. Thanks for taking our questions. And congrats again on the progress.

Thank you.

Our next question comes from the line of Joseph Stringer from Needham & Company. Your line is open.

Hi. Good morning, everyone. Thanks for taking my questions. First one is just a general question on comparing the relative launches from – for IMCIVREE initial launch Baine L'Alleud versus Bardet-Biedl and potential launch for Bardet-Biedl and Alstrom's. What are the – do you expect to sort of hit the ground running in terms of if the approval does come in the second quarter of next year, would you be ready to sort of launch commercially soon thereafter or what are – are there any gating factors around that? And the second question is around the potential contribution ex-US versus US in terms of sales for Bardet-Biedl and Alstrom's. It seems like the patients are a little bit – there's more identified patients ex-US it seems like there's maybe a little bit better infrastructure around patient ID and things like that ex-US. So just curious, if you could compare and contrast US versus ex-US relative contributions to that? Thank you.

Okay. Jennifer, yeah.

I think that there are for sure differences just in terms of the initial launch around IMCIVREE for the PPL indication. One of the biggest differences is just in terms of the teams that were in place to really start the process of educating, and also are facing with our customers. We didn't really have the teams in place for the initial launch also based off of the very low number of PPL that were also diagnosed and our expectations in terms of sales as outlined in the past has been depends in the first couple of years. Things are very different for the BBS launch. We have hired the team that will be in place to really position us for being able to hit the ground running once we get the approval within the BBS indication. And as aforementioned on this call as well there are a significant more number of BBS patients, because of the fact that they're still in enrollment and more easily identified that we would be able to expect to be able to get on to the drug, if we were to get approval next year.

Great. Thanks for taking question.

Okay. Thanks Joe.

Our next question comes from the line of Corinne Jenkins with Goldman Sachs. Your line is open.

Yeah, good morning everybody. Just curious as you've engaged in the various medical conferences you've attended this fall. What have you learned specifically from the community with respect to BBS either on the clinical need or with respect to the physician's view of the setmelanotide profile?

Thanks, Corinne. I'll start and then I'll let Jennifer or Linda chime in. It's interesting how clinical trials focus on p-values and top-line data, but that doesn't capture the full story, especially for BBS and Alstrom's. What's been particularly revealing in the recent data sets are the interviews we conducted. We had exit interviews, which are set to be published soon, and some quotes are included in one of the posters. These quotes allow us to grasp the severe impact of this disease. For instance, you heard a couple of stories today from Linda and Jennifer, but one in particular that stands out is about a young child, just four years old, who was separated from his family because social services mistakenly viewed them as overfeeding him, seeing it as abuse. He spent a year and a half in a facility for something he did not cause. This is the nuance we are observing. Additionally, Jennifer shared market research data indicating that when physicians were presented with the profile of this drug, 75% said they would prescribe it as a first-line treatment. In a field where awareness of the disease is still developing, this indicates a significant recognition of the unmet need. I hope this information is helpful as it highlights what we've learned since our last discussion.

Yeah, that's helpful.

I'll just quickly…

Go ahead.

I'll just quickly tag on and support that, whether it's through the market insights from physicians, or patients, or the interactions with physicians themselves. The aspect of the obesity and hyperphagia even in this syndromic indication really pops up, in terms of being one of the key priorities of addressing within this particular patient population simply because of the impact that it has not only on the patient, but as well as the caregiver family. So it is definitely a need out there where physicians are waiting to have something to be able to specifically address the needs of the patient population.

Thanks. And then as we think about the growth in the URO testing, can you help us understand whether that's primarily driven and how you expect it to be driven on the forward of new HCPs or just existing HCPs that are already doing testing, testing more-and-more patients?

So…

Yeah. Yeah go ahead.

Look, in addition to the territory managers that are on ground, which are a team that's also supporting the ongoing efforts that were put in place through our MSLs. We also have our area development managers. And in terms of testing initiatives, as I outlined in the last earnings call, we have put in place efficiencies around our URO program that should make it easier for physicians to be able to order kits, and test, and see the results. So the initial target will definitely be educating physicians who are already testing, to see if there is interest in terms of increasing the volume, through the efficiencies. But certainly they also have additional targets that are keys just in terms of increasing awareness around RGDO in general, suspecting and then testing as well.

And Corinne, let me add that we recently posted information on our website about our URO testing program. It details the number of kits requested by healthcare providers and the number that have been returned. Approximately 1,400 healthcare providers have sent back kits, which I see as a strong initial indicator of interest from physicians who recognize the potential genetic factors involved. The majority of these providers focus on medical genetics, and all this information is included in the poster. Additionally, regarding your earlier question, the top utilizers are currently generating most of our opportunity, particularly those healthcare providers who have submitted just one test. They have demonstrated interest by taking that step, which indicates a good potential for scaling up. Another interesting detail from the poster is the age distribution of patients being tested: 20% are under six years old, and 30% are between seven and twelve. This means that 50% of the tested patients are children, which is typical for genetic diseases since symptoms often present early, prompting parents to seek assistance. There's much to learn here, and I remain optimistic about the role URO testing will play in our development in this area.

Great, thank you.

Thanks, Corinne. Next question?

There are no further questions at this time. Now I'll turn the call back over to David Meeker.

Great. Well thanks to all of you for tuning in this morning. We look forward to talking to you again in three months' time at the fourth quarter update. That's all. Goodbye. Thanks everyone.

This concludes today's conference call. Thank you for participating. You may now disconnect.